Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Operating Expenses (2016 - 2026)

Ocular Therapeutix has reported Operating Expenses over the past 14 years, most recently at $104.1 million for Q1 2026.

  • For Q1 2026, Operating Expenses rose 39.55% year-over-year to $104.1 million; the TTM value through Mar 2026 reached $351.5 million, up 33.27%, while the annual FY2025 figure was $322.0 million, 36.71% up from the prior year.
  • Operating Expenses for Q1 2026 was $104.1 million at Ocular Therapeutix, up from $83.0 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $104.1 million in Q1 2026 and troughed at $31.0 million in Q1 2022.
  • A 5-year average of $54.9 million and a median of $46.4 million in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: rose 0.73% in 2022 and later skyrocketed 94.14% in 2024.
  • Year by year, Operating Expenses stood at $33.4 million in 2022, then rose by 4.23% to $34.9 million in 2023, then surged by 94.14% to $67.7 million in 2024, then increased by 22.69% to $83.0 million in 2025, then increased by 25.44% to $104.1 million in 2026.
  • Business Quant data shows Operating Expenses for OCUL at $104.1 million in Q1 2026, $83.0 million in Q4 2025, and $83.2 million in Q3 2025.